Novo Nordisk: Big Gains In Diabetes And Obesity Care

Danish pharmaceutical giant Novo Nordisk released its fourth quarter results, reporting $7.1 billion in revenues, up 22% year-over-year compared to $5.8 billion a year ago. With its diabetes and obesity care growing, how is it set to benefit?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.